Annals of Emergency Medicine
Volume 45, Issue 4 , Pages 363-376 , April 2005

2004 American College of Cardiology/American Heart Association Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: Implications for Emergency Department Practice

Received 2 September 2004 ,Revised 15 October 2004 ,Accepted 1 November 2004.

References 

  1. Gunnar RM, Passamani ER, Bourdillon PD, et al. Guidelines for the early management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee to Develop Guidelines for the Early Management of Patients with Acute Myocardial Infarction). J Am Coll Cardiol. 1990;16:249–292
  2. Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1996;28:1328–1428
  3. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1999;34:890–911
  4. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol. 2000;36:970–1062
  5. Pollack CV, Gibler WB. 2000 ACC/AHA guidelines for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction: a practical summary for emergency physicians. Ann Emerg Med. 2001;38:229–240
  6. Pollack CV, Gibler WB. Advances create opportunities: implementing the major tenets of the new unstable angina guidelines in the emergency department. Ann Emerg Med. 2001;38:241–248
  7. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non–ST-segment myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). Available at: http://www.acc.org/clinical/guidelines/unstable/unstable.pdf. Accessed September 1, 2004.
  8. Pollack CV, Roe MT, Peterson ED. 2002 Update to the ACC/AHA guidelines for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction: implications for emergency department practice. Ann Emerg Med. 2003;41:355–369
  9. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Available at: http://www.acc.org/clinical/guidelines/stemi/index.pdf. Accessed August 27, 2004.
  10. Leslie WS, Urie A, Hooper J, et al. Delay in calling for help during myocardial infarction: reasons for the delay and subsequent pattern of accessing care. Heart. 2000;84:137–141
  11. Simon AB, Feinleib M, Thompson HK. Components of delay in the pre-hospital phase of acute myocardial infarction. Am J Cardiol. 1972;30:476–482
  12. Canto JG, Zalenski RJ, Ornato JP, et al. for the National Registry of Myocardial Infarction 2 Investigators Use of emergency medical services in acute myocardial infarction and subsequent quality of care: observations from the National Registry of Myocardial Infarction 2. Circulation. 2002;106:3018–3023
  13. Cummins RO. From concept to standard-of-care? Review of the clinical experience with automated external defibrillators. Ann Emerg Med. 1989;18:1269–1275
  14. Cummins RO, Schubach JA, Litwin PE, et al. Training lay persons to use automatic external defibrillators: success of initial training and one-year retention of skills. Am J Emerg Med. 1989;7:143–149
  15. Mosesso VN, Davis EA, Auble TE, et al. Use of automated external defibrillators by police officers for treatment of out-of-hospital cardiac arrest. Ann Emerg Med. 1998;32:200–207
  16. Valenzuela TD, Roe DJ, Nichol G, et al. Outcomes of rapid defibrillation by security officers after cardiac arrest in casinos. N Engl J Med. 2000;343:1206–1209
  17. Page RL, Joglar JA, Kowal RC, et al. Use of automated external defibrillators by a US airline. N Engl J Med. 2000;343:1210–1216
  18. Ornato JP, Racht EM, Fitch JJ, et al. The need for ALS in urban and suburban EMS systems. Ann Emerg Med. 1990;19:1469–1470
  19. Eisenberg MJ, Topol EJ. Prehospital administration of aspirin in patients with unstable angina and acute myocardial infarction. Arch Intern Med. 1996;156:1506–1510
  20. Armstrong PW, Collen D, Antman E. Fibrinolysis for acute myocardial infarction: the future is here and now. Circulation. 2003;107:2533–2537
  21. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group . Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1,000 patients. Lancet. 1994;343:311–322
  22. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI) . Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;1:397–402
  23. Weaver WD, Cerqueira M, Hallstrom AP, et al. Prehospital-initiated vs hospital-initiated thrombolytic therapy: the Myocardial Infarction Triage and Intervention trial. JAMA. 1993;270:1211–1216
  24. Hermens WT, Willems GM, Nijssen KM, et al. Effect of thrombolytic treatment delay on myocardial infarct size. [letter] Lancet. 1992;340:1297
  25. Gersh BJ, Anderson JL. Thrombolysis and myocardial salvage: results of clinical trials and the animal paradigm: paradoxic or predictable?. Circulation. 1993;88:296–306
  26. Newby LK, Rutsch WR, Califf RM, et al. for the GUSTO-1 Investigators Time from symptom onset to treatment and outcomes after thrombolytic therapy. J Am Coll Cardiol. 1996;27:1646–1655
  27. Milavetz JJ, Giebel DW, Christian TF, et al. Time to therapy and salvage in myocardial infarction. J Am Coll Cardiol. 1998;31:1246–1251
  28. Chareonthaitawee P, Gibbons RJ, Roberts RS, et al. for the CORE investigators (Collaborative Organisation for RheothRx Evaluation) The impact of time to thrombolytic treatment on outcome in patients with acute myocardial infarction. Heart. 2000;84:142–148
  29. The European Myocardial Infarction Project Group . Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. N Engl J Med. 1993;329:383–389
  30. Steg PG, Bonnefoy E, Chabaud S, et al. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation. 2003;108:2851–2856
  31. Widimsky P, Budesinsky T, Vorac D, et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction: final results of the randomized national multicentre trial—PRAGUE-2. Eur Heart J. 2003;24:94–104
  32. Pedley DK, Bissett K, Connolly EM, et al. Prospective observational cohort study of time saved by prehospital thrombolysis for ST elevation myocardial infarction delivered by paramedics. BMJ. 2003;327:22–26
  33. Hochman JS, Sleeper LA, White HD, et al. for the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) Investigators One-year survival following early revascularization for cardiogenic shock. JAMA. 2001;285:190–192
  34. Topol EJ, Kereiakes DJ. Regionalization of care for acute ischemic heart disease: a call for specialized centers. Circulation. 2003;107:1463–1466
  35. Califf RM, Faxon DP. Need for centers to care for patients with acute coronary syndromes. Circulation. 2003;107:1467–1470
  36. Willerson JT. Editor's commentary: centers of excellence. Circulation. 2003;107:1471–1472
  37. Farkouh ME, Smars PA, Reeder GS, et al. for the Chest Pain Evaluation in the Emergency Room (CHEER) Investigators A clinical trial of a chest-pain observation unit for patients with unstable angina. N Engl J Med. 1998;339:1882–1888
  38. Cannon CP, Antman EM, Walls R, et al. Time as an adjunctive agent to thrombolytic therapy. J Thromb Thrombolysis. 1994;1:27–34
  39. Menown IB, Mackenzie G, Adgey AA. Optimizing the initial 12-lead electrocardiographic diagnosis of acute myocardial infarction. Eur Heart J. 2000;21:275–283
  40. Luepker RV, Apple FS, Christenson RH, et al. Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. Circulation. 2003;108:2543–2549
  41. Adams JE, Abendschein DR, Jaffe AS. Biochemical markers of myocardial injury: is MB creatine kinase the choice for the 1990s?. Circulation. 1993;88:750–763
  42. Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography) [American College of Cardiology Web site]. Available at: http://www.acc.org/clinical/guidelines/echo/index.pdf. Accessed August 28, 2004.
  43. Waters RE, Singh KP, Roe MT, et al. Rationale and strategies for implementing community-based transfer protocols for primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004;43:2153–2159
  44. Aubier M, Trippenbach T, Roussos C. Respiratory muscle fatigue during cardiogenic shock. J Appl Physiol. 1981;51:499–508
  45. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet. 1995;345:669–685
  46. Cheitlin MD, Hutter AM, Brindis RG, et al. ACC/AHA expert consensus document on the use of sildenafil (Viagra) in patients with cardiovascular disease: American College of Cardiology/American Heart Association. J Am Coll Cardiol. 1999;33:273–282
  47. First International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1. Lancet. 1986;2:57–66
  48. The MIAMI Trial Research Group . Metoprolol in acute myocardial infarction: patient population. Am J Cardiol. 1985;56:10G–14G
  49. Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730–1737
  50. Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation. 1991;83:422–437
  51. Van de Werf F, Janssens L, Brzostek T, et al. Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardic agent in patients with acute myocardial infarction receiving thrombolytic therapy. J Am Coll Cardiol. 1993;22:407–416
  52. Pfisterer M, Cox JL, Granger CB, et al. Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience: Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries. J Am Coll Cardiol. 1998;32:634–640
  53. Collins R, Peto R, Baigent C, et al. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med. 1997;336:847–860
  54. Eisenberg PR. Role of heparin in coronary thrombolysis. Chest. 1992;101:131S–139S
  55. Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial: phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988;11:1–11
  56. Popma JJ, Califf RM, Ellis SG, et al. Mechanism of benefit of combination thrombolytic therapy for acute myocardial infarction: a quantitative angiographic and hematologic study. J Am Coll Cardiol. 1992;20:1305–1312
  57. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330–1335
  58. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators . Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet. 2001;358:605–613
  59. Montalescot G, Barragan P, Wittenberg O, et al. for the Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up (ADMIRAL) Investigators Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895–1903
  60. Stone GW, Grines CL, Cox DA, et al. for the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002;346:957–966
  61. Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care: part 6: advanced cardiovascular life support: section 5: pharmacology I: agents for arrhythmias: the American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Circulation. 2000;102:I112–I128
  62. The Danish Study Group on Verapamil in Myocardial Infarction . Verapamil in acute myocardial infarction. Eur Heart J. 1984;5:516–528
  63. The Multicenter Diltiazem Postinfarction Trial Research Group . The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 1988;319:385–392
  64. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361:13–20
  65. Magid DJ, Calonge BN, Rumsfeld JS, et al. for the National Registry of Myocardial Infarction 2 and 3 Investigators Relation between hospital primary angioplasty volume and mortality for patients with acute MI treated with primary angioplasty vs thrombolytic therapy. JAMA. 2000;284:3131–3138
  66. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349–360
  67. Wilcox RG, von der Lippe G, Olsson CG, et al. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet. 1988;2:525–530
  68. AIMS Trial Study Group . Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study. Lancet. 1990;335:427–431
  69. Van de Werf F. Thrombolysis for acute myocardial infarction: why is there no extra benefit after hospital discharge?. Circulation. 1995;91:2862–2864
  70. White HD. Thrombolytic therapy in the elderly. Lancet. 2000;356:2028–2030
  71. Brass LM, Lichtman JH, Wang Y, et al. Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. Stroke. 2000;31:1802–1811
  72. Gurwitz JH, Gore JM, Goldberg RJ, et al. for the Participants in the National Registry of Myocardial Infarction 2 Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Ann Intern Med. 1998;129:597–604
  73. Simoons ML, Maggioni AP, Knatterud G, et al. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. Lancet. 1993;342:1523–1528
  74. Sloan MA, Guigliano RP, Thompson SL. Prediction of intracranial hemorrhage in the InTIME-II trial. J Am Coll Cardiol. 2001;37:372A
  75. Walls RM, Pollack CV, NEAR Investigators . Successful cricothyrotomy after thrombolytic therapy for acute myocardial infarction: a report of two cases. Ann Emerg Med. 2000;35:188–191
  76. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomized trial: Assessment of the Safety and Efficacy of a New Thrombolytic Investigators. Lancet. 1999;354:716–722
  77. Gore JM, Granger CB, Simoons ML, et al. Stroke after thrombolysis: mortality and functional outcomes in the GUSTO-I trial: Global Use of Strategies to Open Occluded Coronary Arteries. Circulation. 1995;92:2811–2818
  78. Sloan MA, Sila CA, Mahaffey KW, et al. Prediction of 30-day mortality among patients with thrombolysis-related intracranial hemorrhage. Circulation. 1998;98:1376–1382
  79. Holper EM, Giugliano RP, Antman EM. Glycoprotein IIb/IIIa inhibitors in acute ST-segment myocardial infarction. Coronary Artery Dis. 1999;10:567–573
  80. Antman EM, Giugliano RP, Gibson CM, et al. for the TIMI-14 Investigators Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial. Circulation. 1999;99:2720–2732
  81. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group . Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Circulation. 2000;101:2788–2794
  82. Brener SJ, Zeymer U, Adgey AA, et al. Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the Integrilin and Low-Dose Thrombolysis in Acute Myocardial Infarction (INTRO AMI) trial. J Am Coll Cardiol. 2002;39:377–386
  83. Topol EJ for the GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet. 2001;357:1905–1914
  84. Weaver WD, Simes RJ, Betriu A, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA. 1997;278:2093–2098
  85. Grines C, Patel A, Zijlstra J, et al. Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials. Am Heart J. 2003;145:47–57
  86. Grzybowski M, Clements EA, Parsons L, et al. Mortality benefit of immediate revascularization of acute ST-segment elevation myocardial infarction in patients with contraindications to thrombolytic therapy: a propensity analysis. JAMA. 2003;290:1891–1898
  87. Berger PB, Ellis SG, Holmes DR, et al. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. Circulation. 1999;100:14–20
  88. Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA. 2000;283:2941–2947
  89. Nallamothu BK, Bates ER. Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything?. Am J Cardiol. 2003;92:824–826
  90. Juliard JM, Feldman LJ, Golmard JL, et al. Relation of mortality of primary angioplasty during acute myocardial infarction to door-to-Thrombolysis In Myocardial Infarction (TIMI) time. Am J Cardiol. 2003;91:1401–1405
  91. Bonnefoy E, Lapostolle F, Leizorovicz A, et al. for the Comparison of Angioplasty and Prehospital Thrombolysis in Acute Myocardial Infarction Study Group Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet. 2002;360:825–829
  92. Zijlstra F, van't Hof AW, Liem AL, et al. Transferring patients for primary angioplasty: a retrospective analysis of 104 selected high-risk patients with acute myocardial infarction. Heart. 1997;78:333–336
  93. Zahn R, Schiele R, Seidl K, et al. Primary angioplasty in acute myocardial infarction: differences between referred patients and those treated in hospitals with on-site facilities?. J Invasive Cardiol. 1999;11:213–219
  94. Straumann E, Yoon S, Naegeli B, et al. Hospital transfer for primary coronary angioplasty in high-risk patients with acute myocardial infarction. Heart. 1999;82:415–419
  95. Ross AM, Coyne KS, Reiner JS, et al. for the Plasminogen-activator Angioplasty Compatibility Trial (PACT) investigators. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. J Am Coll Cardiol. 1999;34:1954–1962
  96. Fernandez-Aviles F, Alonso JJ, Castro-Beiras A, et al. Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach to acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomized controlled trial. Lancet. 2004;364:1045–1053
  97. Kastrati A, Mehilli J, Schlotterbeck K, et al. for the Bavarian Reperfusion Alternatives Evaluation (BRAVE) Study Investigators Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial. JAMA. 2004;291:947–954

 Funding and support: All authors have received honoraria or research support (direct or indirect) from Aventis Pharmaceuticals, Millennium Pharmaceuticals, Schering-Plough, Bristol-Myers-Squibb, and Sanofi, which market therapeutic agents cited in this article. Dr. Pollack has received honoraria from Genentech.Reprints not available from the authors.

PII: S0196-0644(04)01617-8

doi: 10.1016/j.annemergmed.2004.11.003

Annals of Emergency Medicine
Volume 45, Issue 4 , Pages 363-376 , April 2005

Article Tools

* Image Usage & Resolution